Ketamine for Anxiety and PTSD: When Traditional Treatment Isn't Enough

Key Takeaways:

• IV ketamine offers 100% bioavailability and real-time dose control during 40-60 minute infusions

• IM ketamine provides 93% bioavailability with rapid onset and no IV equipment needed

• Sublingual lozenges offer 25-35% bioavailability, ideal for therapy integration and at-home use

• All three methods show effectiveness for depression, PTSD, and anxiety

• IV is typically preferred for chronic pain and complex medical conditions

• Lozenges are most commonly used in ketamine-assisted psychotherapy (KAP) settings

• Your choice depends on medical needs, therapeutic goals, and treatment setting

You're considering ketamine therapy. Maybe you've tried traditional antidepressants without relief. Maybe you're managing chronic pain that won't let up. Or maybe you're just tired of waiting weeks or months for medications to work…if they work at all.

Ketamine has been shown to be effective for depression, PTSD, and anxiety.

Now you're facing another decision: IV infusion, IM injection, or sublingual lozenge?

The route matters. Not just for how the treatment feels, but for how well it works, how safely it's delivered, and whether it's the right fit for your body, your life, and your therapeutic goals.

This guide breaks down the differences so you can make an informed choice.

What is Ketamine?

Ketamine was first synthesized in 1962 and approved by the FDA in 1970 as a dissociative anesthetic and analgesic. For decades, it was used in emergency rooms and operating theaters because of its safety profile; it maintains respiratory function even at anesthetic doses.

In the early 2000s, researchers at Yale and the National Institute of Mental Health began demonstrating something remarkable: ketamine could rapidly alleviate symptoms of severe depression. Within hours, not weeks.

That discovery changed the conversation around psychiatric treatment.

How Ketamine Works in the Brain

Traditional antidepressants target serotonin and norepinephrine. They can take weeks or months to yield results, and they don't work for everyone.

Ketamine works differently.

It acts on the brain's primary excitatory neurotransmitter, glutamate, by blocking N-methyl-D-aspartate (NMDA) receptors. This creates a controlled surge of glutamate that increases the production of Brain-Derived Neurotrophic Factor (BDNF), often described as "Miracle-Gro" for brain cells.

What this means practically:

Ketamine promotes neuroplasticity. It helps the brain repair and rewire itself by growing new synaptic connections in areas damaged by chronic stress and depression, primarily the prefrontal cortex and hippocampus.

The result? Relief from depressive symptoms and suicidal ideation often within hours of the first treatment. No other psychiatric medication works this fast.

Conditions Treated with Ketamine

While ketamine is best known for treatment-resistant depression (TRD) and acute suicidal ideation, its therapeutic benefits extend to:

• Major Depressive Disorder (MDD)

• Anxiety Disorders and OCD

• Post-Traumatic Stress Disorder (PTSD)

• Chronic Pain Conditions (Complex Regional Pain Syndrome, neuropathic pain, severe migraines)

• Substance Use Disorders (when integrated with psychotherapy)

Understanding Administration Methods

The route by which ketamine enters your bloodstream (the route of administration) is one of the most critical factors influencing your clinical experience, safety profile, and therapeutic outcome.

In a clinical setting, IV (intravenous), IM (intramuscular), and sublingual lozenges are all considered safe and effective when administered under proper medical supervision. But they differ significantly in key ways.

IV Ketamine: The Intravenous Approach

How IV Ketamine Works

IV ketamine is considered the "gold standard" route in many clinical settings. A small catheter is placed into a vein, and the calculated dose of ketamine is mixed into a saline solution and delivered slowly and steadily via an infusion pump over 40 to 60 minutes.

Dosage and Onset

The standard protocol for depression involves an infusion of around 0.5 mg/kg over 40 minutes, often administered as a series of 6 treatments over 2-3 weeks. For chronic pain conditions, the dosage may be higher, and the infusion may last several hours.

Onset: Effects begin immediately (within seconds) as the medication enters the bloodstream directly.

Duration of Peak Effect: The controlled, gradual administration yields a smoother, more sustained therapeutic effect throughout the entire 40-60 minute session, providing a longer therapeutic window for reflection and processing.

Bioavailability: 100% all of the medication reaches the brain.

Benefits of IV Ketamine

Precise Dosage Control (Titration)

The infusion rate can be adjusted in real time by the provider, allowing for careful management of the patient's experience and any side effects that arise.

Consistent Delivery

Because IV administration bypasses the variability of absorption, it tends to produce a more predictable clinical experience than other routes, which some patients and providers prefer.

Safety and Monitoring

The ability to slow or stop the infusion if needed makes IV a thoughtful choice for patients with underlying medical concerns or those approaching ketamine for the first time.

Chronic Pain Management

IV ketamine has been used in clinical settings for certain chronic pain conditions. Whether this is an appropriate application is determined through careful screening and consultation with your treatment team.

Potential Downsides

IV ketamine carries a low risk of vein irritation, and the process requires catheter placement (which some patients dislike). You're restricted by the IV line and pump for 40-60 minutes.

Side effects include transient blood pressure increases, nausea, and dizziness—but are often more easily managed due to the ability to titrate the dose.

IM Ketamine: The Intramuscular Approach

How IM Ketamine Works

IM ketamine is administered via a single injection into a large muscle, typically the deltoid (upper arm) or gluteal muscle. The full, calculated dose is delivered in one shot.

Dosage and Onset

Dosages are carefully calculated by weight (typically 0.5 to 1.0 mg/kg). The full amount is injected at once.

Onset: Effects begin rapidly—within 1 to 5 minutes of the injection.

Duration of Peak Effect: The experience tends to be quicker and more intense, with peak effects lasting approximately 30 to 45 minutes.

Bioavailability: Approximately 93%—nearly all of the medication reaches the brain.

Benefits of IM Ketamine

Ease of AdministrationSimple injection requiring no sustained IV access. Ideal for patients with difficult veins or needle anxiety about IV placement.

Rapid OnsetThe quick onset is favored by some patients who prefer a faster transition into the therapeutic state.

Flexibility and CostSessions are generally shorter than IV infusions, making them more time-efficient and often more affordable. You're not tethered to an IV line, which some patients prefer for comfort and movement.

Group Therapy SettingsIM is often used in group ketamine-assisted psychotherapy sessions where mobility and shorter duration are advantageous.

Potential Downsides

Because the full dose is administered at once, the rapid peak can lead to a more intense or abrupt experience for some patients. Once the injection is given, the dose cannot be adjusted.

Common, transient side effects include mild nausea, dizziness, and temporary increases in heart rate or blood pressure—all managed by clinical staff.

Sublingual Lozenges: The Oral Approach

How Ketamine Lozenges Work

Ketamine lozenges (also called troches) are placed under the tongue where the medication is absorbed through the mucous membranes. This is the sublingual route. The lozenge typically dissolves over 10-15 minutes.

Dosage and Onset

Dosages for sublingual lozenges range from 200 mg to 600 mg or higher, depending on the therapeutic goal and patient response. While the milligram numbers sound high, the actual amount reaching the brain is much lower due to reduced bioavailability.

Onset: Effects begin within 15-30 minutes as the medication is absorbed.

Duration of Peak Effect: The experience is gentler and more extended, typically lasting 60-90 minutes of active effects. The absorption is slower and more gradual than IV or IM.

Bioavailability: Approximately 25-35%, significantly lower than IV or IM, which is why higher doses are used.

Benefits of Sublingual Lozenges

Ideal for Ketamine-Assisted Psychotherapy (KAP)

The extended, gentler experience is optimal for deep therapeutic work. The slower absorption allows for sustained emotional processing and integration within the session.

No Needles Required

No injections, no IV placement. The lozenge is simply placed under the tongue.

At-Home Use (With Proper Screening)

In some treatment protocols, lozenges can be prescribed for at-home use between in-office sessions, allowing for more frequent dosing and continuity of care.

Lower Intensity

The gradual onset and lower bioavailability create a less intense, more manageable experience for many patients—particularly those new to ketamine or working with trauma.

Longer Sessions for Therapy

The 60-90 minute active window is perfect for state-dependent psychotherapy, where the goal is to work within the altered state to process emotions, memories, and patterns.

Potential Downsides

The lower bioavailability means higher doses are required to achieve therapeutic effects. Some patients don't like the taste or the sensation of holding the lozenge under their tongue.

Because absorption is gradual and variable, the experience can be less predictable than IV or IM. Some patients don't achieve sufficient therapeutic effects with lozenges alone.

Comparing All Three Routes

The decision between IV, IM, and lozenges often comes down to balancing control, convenience, and therapeutic context.

Efficacy and Clinical Outcomes

General Efficacy: Research shows that IV, IM, and sublingual ketamine can all produce significant improvements in depression, anxiety, and PTSD symptoms. A randomized study comparing IV and IM found comparable 57-60% reductions in depression scores within two hours.

IV Advantage: Due to 100% bioavailability and precise dose control, IV is often associated with the most consistent outcomes and is generally preferred for complex medical histories and chronic pain.

IM Advantage: Rapid, intense onset makes IM effective for acute symptom relief and is often used in clinical settings where IV equipment isn't practical.

Lozenge Advantage: The extended, gentler experience is ideal for psychotherapy integration. When paired with skilled therapeutic support, lozenges excel for trauma processing, attachment work, and emotional access.

Safety Considerations

All three routes are safe when administered in a proper clinical setting with appropriate monitoring (vital signs, oxygen saturation, cardiac monitoring).

Safety Control:

• IV: Highest level of real-time control—dose can be stopped or adjusted instantly.

• IM: Dose cannot be adjusted once given, but rapid screening and preparation mitigate risks.

• Lozenges: Gradual absorption reduces intensity of side effects. Patients can spit out the lozenge if needed, though some medication has already been absorbed.

Patient Experience Comparison

Factor	IV Ketamine	IM Ketamine	Sublingual Lozenges
Onset	Immediate (seconds)	Rapid (1-5 minutes)	Gradual (15-30 minutes)
Peak Duration	40-60 minutes	30-60 minutes	60-90 minutes
Bioavailability	100%	93%	25-35%
Intensity	Smooth, controlled	Fast, intense	Gentle, extended
Mobility	Restricted by IV line	Free to move after injection	Full mobility throughout
Needle Required	IV catheter (40-60 min)	Single quick injection	None
Session Length	60-90 minutes total	45-60 minutes total	2-3 hours (for therapy integration)
Dose Adjustability	Real-time adjustments	No adjustments once given	Can discontinue by spitting out
Best For	Medical complexity, chronic pain, first-timers	Rapid relief, group settings, efficiency	KAP, trauma work, at-home protocols

A Common Starting Point

For many patients, the most effective path begins with IV or IM ketamine. These routes offer a faster, more immediate entry into the neuroplastic window, which can be especially valuable early in treatment when symptom relief and momentum matter most. As the work deepens and the therapeutic relationship develops, many patients transition to sublingual lozenges for ongoing sessions. Occasional maintenance IV or IM sessions, typically monthly, can be integrated to sustain and reinforce the gains made in psychotherapy.

Group Sessions

For patients working with IM ketamine, Higher Ground offers monthly group immersions at the Westport and Woodbury studio locations. Group sessions provide the same clinically guided, therapist-led protocol as individual work, in an intentionally small, held setting. They are also a more accessible option for patients who want to continue the work with greater frequency.

Higher Ground studio located in Westport, CT

Monthly Sunday sessions begin this spring. Space is limited. Learn more and reserve your spot at highergroundct.com/kap-intensives.

At Higher Ground, we work with you to determine which route aligns with your medical profile, comfort level, and therapeutic goals. Our approach emphasizes ketamine-assisted psychotherapy using sublingual lozenges in extended sessions, allowing for the deep work that creates lasting change.

Ready to Explore Ketamine Therapy?

If you've been battling treatment-resistant depression, chronic pain, PTSD, anxiety, or substance use challenges—and traditional treatments haven't provided relief—ketamine therapy might offer a different path forward.

Explore our KETAMINE-ASSISTED PSYCHOTHERAPY program to learn more about how we integrate ketamine lozenges into ongoing therapeutic support for trauma processing, emotional access, and lasting change.

Or reach out to schedule a consultation to discuss which route is right for you.

Your healing deserves precision, intention, and expert care.

Frequently Asked Questions

What's the main difference between IV, IM, and lozenge ketamine?

IV delivers ketamine directly into the bloodstream with 100% bioavailability and real-time dose control. IM is a single injection with 93% bioavailability and rapid onset. Lozenges are absorbed under the tongue with 25-35% bioavailability and a gentler, extended experience ideal for therapy integration.

Is one method more effective than the others?

All three routes show clinical effectiveness. IV may offer slight advantages for chronic pain and complex medical conditions. IM excels for rapid symptom relief. Lozenges are optimal for ketamine-assisted psychotherapy and trauma work due to their extended therapeutic window.

Which method is safest?

All three are safe when administered properly with medical monitoring. IV offers the most real-time control. IM and lozenges are also very safe with appropriate screening. Lozenges may feel safest to some patients due to their gradual onset and ability to discontinue if needed.

Why do lozenges require such high doses if they're effective?

Sublingual absorption has lower bioavailability (25-35%) compared to IV (100%) or IM (93%). So while the milligram dose is higher, the actual amount reaching the brain is therapeutic—not excessive. The gentler absorption curve is actually beneficial for psychotherapy integration.

Can I switch between methods during my treatment course?

Yes. Some patients start with IV for a controlled introduction, then transition to IM or lozenges for maintenance. Others use lozenges for ongoing therapy and IM or IV for acute symptom relief. Your provider will work with you to adjust your protocol based on response and goals.

Which method does Higher Ground use?

Higher Ground specializes in ketamine-assisted psychotherapy using sublingual lozenges. This allows for extended, immersive therapeutic sessions (2-3 hours) where we work within the neuroplastic window ketamine creates. We focus on trauma processing, attachment repair, and deep emotional work—not just symptom relief.

How do I know which route is right for me?

Schedule a consultation. We'll discuss your medical history, mental health symptoms, treatment goals, comfort level, and therapeutic needs. Together, we'll determine which route, or combination of routes, best serves your healing journey.

Sources

Chilukuri H, Reddy NP, Pathapati RM, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian Journal of Psychological Medicine. 2014;36(1):71-76.

Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry. 2018;23(4):801-811.

Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Reports. 2018;23(11):3170-3182.

Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clinical Pharmacokinetics. 2016;55(9):1059-1077.

Glue P, Russell B, Medlicott NJ. Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review. European Journal of Clinical Pharmacology. 2021;77(1):3-13.

Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of Psychiatry. 2012;169(8):868-869.

Loo CK, Gálvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica. 2016;134(1):48-56.

McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry. 2021;178(5):383-399.

Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A paradigm shift for depression research and treatment. Neuron. 2019;101(5):774-778.

Andrade C. Ketamine for depression, 4: In what dose, at what rate, by what route, for how long, and at what frequency? Journal of Clinical Psychiatry. 2017;78(7):e852-e857.

Dore J, Turnipseed B, Dwyer S, et al. Ketamine-assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs. 2019;51(2):189-198.

Wolfson P, Hartelius G. The Ketamine Papers: Science, Therapy, and Transformation. Multidisciplinary Association for Psychedelic Studies (MAPS). 2016.